Presently, the phase III TROPION-Breast04 trial (NCT06112379) is further evaluating the efficacy and safety of Dato-DXd and durvalumab in neoadjuvant or adjuvant settings for TNBC or HR-low/HER2- breast cancer (67). Here, ERBB2 is linked to breast carcinoma.